MARKET

TENX

TENX

Tenax Therapeutics Inc
NASDAQ
3.560
+0.060
+1.71%
After Hours: 3.470 -0.09 -2.53% 17:47 04/24 EDT
OPEN
3.610
PREV CLOSE
3.500
HIGH
3.630
LOW
3.480
VOLUME
7.88K
TURNOVER
0
52 WEEK HIGH
61.20
52 WEEK LOW
3.480
MARKET CAP
6.97M
P/E (TTM)
-0.1147
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TENX last week (0415-0419)?
Weekly Report · 2d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Tian Ruixiang (NASDAQ:TIRX) stock is rocketing more than 151% after announcing plans for an extraordinary shareholders meeting. MicroCloud Hologram shares are soaring over 52% alongside heavy pre-market trading. Earnings reports, shareholder meetings, public offerings and more are moving stocks this morning. Biggest Pre-Market Stock Movers: 10 Top Gainers.
Investorplace · 6d ago
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Alcoa Corporation rose sharply in today’s pre-market trading after the company reported better-than-expected sales for its first quarter. The company shares jumped 3% to $36.60 in pre- market trading. Tian Ruixiang Holdings Ltd (NASDAQ:TIRX) shares gained 155.6% in today's trading.
Benzinga · 6d ago
Weekly Report: what happened at TENX last week (0408-0412)?
Weekly Report · 04/15 09:36
Weekly Report: what happened at TENX last week (0401-0405)?
Weekly Report · 04/08 09:38
Weekly Report: what happened at TENX last week (0325-0329)?
Weekly Report · 04/01 09:37
TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023
Tenax Therapeutics reported earnings per share of -$11.84 for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for -$8.14. Tenax Therapedutics reported results for the last quarter of 2018.
Investorplace · 03/29 01:54
Tenax Therapeutics: Q4 Earnings Insights
Tenax Therapeutics reported its Q4 earnings results on March 28. The company missed estimated earnings by -45.0%. Tenax TherAPEutics is expected to report its earnings on Thursday, March 28, 2024 at 08:30am. Last quarter the company beat on EPS by $1.6 and was followed by a 19.0% drop in the shares.
Benzinga · 03/28 21:05
More
About TENX
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

Webull offers Tenax Therapeutics Inc stock information, including NASDAQ: TENX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TENX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TENX stock methods without spending real money on the virtual paper trading platform.